Biomarkers uPA/PAI-1 in breast cancer: Benefit and harm of the test unclear

October 20, 2014

To make a decision for or against adjuvant chemotherapy, a test to measure the concentrations of the biomarkers uPA and PAI-1 in the tumour tissue is available for breast cancer patients. However, as suitable studies are lacking, it remains unclear for patients with an intermediate risk of recurrence which benefit or harm a treatment strategy based on this test may have for them. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 20 October 2014.

Adjuvant systemic treatments aim to prolong survival

Even if the breast cancer was completely removed in surgery, the tumour can come back. The risk of such a recurrence can be low, intermediate or high. Adjuvant systemic treatments including chemotherapy are used to lower the risk of recurrence and prolong survival. Until now, whether or not they are used has mostly been determined by the patients' age, the number of lymph nodes affected and the grade of the tumour cells.

Predictive markers aim to improve treatment decision

Whereas generally no chemotherapy is recommended for patients with low risk of recurrence, doctors usually recommend adjuvant treatment for patients with high risk of recurrence. However, for patients with an intermediate risk, the established factors (including grade of the tumour cells) are not sufficient to make such a treatment recommendation. This is why the guidelines do not contain any such recommendations.

In order to make better treatment decisions in patients with intermediate risk of recurrence, and to potentially spare them from the burden of chemotherapy, researchers are investigating so-called biomarkers. These biomarkers aim to help identify those patients who are very likely to benefit from chemotherapy.

High concentration is associated with poor prognosis

The two proteins urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 could be this kind of biomarkers. Both play an important role in metabolic processes taking place in the tumour. If their concentration in the tumour tissue is high, there is also a higher probability of recurrence.

IQWiG was commissioned to investigate whether uPA and PAI-1 are also suited as so-called predictive markers and whether treating staff and patients can base their decisions for or against chemotherapy on the results of corresponding tests.

Design of the only study was unsuitable

IQWiG found one study (the Chemo N0 study) that investigated the benefit of adjuvant chemotherapy in patients with high concentrations of uPA and PAI-1. However, its design was unsuitable to comprehensively answer the research question of the report.

On the one hand, patients with high concentration of the marker who received chemotherapy had no survival advantage (disease-free survival and overall survival) in comparison with patients without chemotherapy. On the other hand, the benefit of chemotherapy was not investigated in patients with low concentration of uPA and PAI-1.

As suitable studies are lacking, the benefit or harm of a strategy based on uPA and PAI-1 for or against chemotherapy therefore remain unclear.
-end-
Process of report production

IQWiG published the preliminary results in the form of the preliminary report in March 2014 and interested parties were invited to submit comments. At the end of the commenting procedure, the preliminary report was revised and sent as a final report to the commissioning agency in August 2014. The written comments submitted were published in a separate document at the same time as the final report. The report was produced in collaboration with external experts.

The executive summary provides an overview of the background, procedure and further results of the Report.

Institute for Quality and Efficiency in Health Care

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.